Puma Biotechnology Third Quarter 2026 Results Call - PUMA BIOTECHNOLOGY INC

Financial Performance:

• Total Q3 2026 revenue: $55.1 million (Product revenue net: $54.1 million; Royalty revenue: ~$1 million).
• Product revenue net increased 1% QoQ ($53.6M to $54.1M) and 4% YoY ($51.9M).
• Gross revenue from Nerlix (Neuralink) sales was $75.1 million, with net product revenue of $54.1 million.
• Royalty revenue dropped 63% QoQ and 62% YoY, driven by a $2.1M cumulative reduction due to generic market share thresholds being met in China.
• Net income (GAAP): $6 million ($0.11/share); Net income (Non-GAAP): $8 million ($0.15/share).
• Gross-to-net adjustments increased to 28% in Q3 from 27.9% in Q2, primarily due to higher Medicaid share.
• Cost of sales was $15.2 million (vs. $12.5M in Q2), including $2.4M amortization of intangible assets.
• Cash generated from operations: $14.7 million; Cash and equivalents (Sept 30, 2026): $108.5 million.
• Company is now debt-free following the final principal loan payment of $11.1 million in Q2.
• Accounts receivable balance: $32.8 million with DSO of 44 days; Distribution inventory approx. two weeks.

Guidance and Future Outlook:

• Full Year 2026 Nerlix net product revenue guidance: $205–$208 million.
• Full Year 2026 royalty revenue guidance: $18–$19 million.
• Full Year 2026 Net Income guidance: $20–$22 million (higher than prior guidance of $17–$20M).
• Full Year 2026 Gross-to-Net guidance: 27.5%–28%.
• Q4 2026 Nerlix net product revenue guidance: $56–$58 million.
• Q4 2026 Royalty revenue guidance: $11–$12 million; No license revenue expected.
• Q4 2026 Gross-to-Net guidance: 28%–29%; Q4 Net Income guidance: $10–$12 million.
• 2026 R&D expenses expected to increase 28–30% YoY; SG&A expected to remain flat.
• Phase 3 trial design for Alisertib in breast cancer to be discussed with regulators in H1 2027.
• Management anticipates two consecutive years of YoY demand growth for Nerlix in the US for the first time since launch.

Business Segments and Product Lines:

• Nerlix (Neuralink): Core revenue driver; 2,818 ex-factory bottles sold in Q3 (4% QoQ decline, 4% YoY decline in volume, though demand grew 3% QoQ and 5% YoY).
• Distribution Channels: Specialty Distributor (SD) channel accounted for 61% of sales (growing at 19% YoY); Specialty Pharmacy (SP) accounted for 39% (prescriptions flat YoY, down 5% QoQ).
• Clinical Trials:
  • ALISCA Breast 1: Phase 2 trial of Alisertib + endocrine therapy for HER2- HR+ breast cancer; enrollment restricted to 40mg and 50mg doses; interim data expected Dec at San Antonio Breast Cancer Symposium; supports moving to Phase 3.
  • ALISCA Lung 1: Phase 2 monotherapy for small cell lung cancer; dose increased to 70mg BID; additional interim data expected 2027.
  • ALISCA Lung 2: Phase 2 trial of Alisertib + paclitaxel; initial data expected 2027.
• International: Q1 2026 launch in Thailand in extended adjuvant setting; product supply revenue to ex-U.S. partners was $3.6M in Q3.
• In-Licensing: Evaluating commercial and development-stage assets for in-licensing/acquisition to diversify portfolio.

Market and Competitive Landscape:

• Market share of generic Nerlix in China reached a threshold triggering royalty rate reductions.
• Management notes continued unmet need in HER2-positive early-stage breast cancer and small cell lung cancer.
• SD channel growth driven by Group Purchasing Organizations (GPOs) and 340B program expansion.
• Competitive pressure in China impacting royalty structures; no new license revenue expected in 2026.
• Tariffs are not currently expected to have a material impact on product costs (manufacturing is mid-to-high single-digit % of COGS).

Risks and Challenges:

• Inventory drawdown of ~$1.5M in Q3 (vs. $1M in Q2) and ~82 bottles, impacting top-line revenue recognition.
• Decline in new patient starts (-13% QoQ, -9% YoY) and total prescriptions (-5% QoQ).
• Sales activity declined 8% YoY due to temporary vacancies and leave.
• Regulatory uncertainty regarding Phase 3 trial design for Alisertib in breast cancer.
• Potential for future tax valuation allowance adjustments not included in current guidance.
• Volatility in trade policies and tariffs.

Management Commentary and Tone:

• Tone is cautiously optimistic regarding financial discipline and profitability, expressing pride in achieving two consecutive years of US demand growth.
• Strong emphasis on "positive net income" as a fiscal responsibility and priority.
• Management acknowledges commercial headwinds (volume dip) but attributes them to temporary factors (inventory drawdown, staffing) and highlights channel shifts toward SD.
• Confident in the clinical data supporting Alisertib's Phase 3 potential in breast cancer.
• Committed to cost control, potentially reducing expenses to maintain profitability if needed.

Analyst Questions and Answers:

• Note: Specific Q&A dialogue details are not fully transcribed in the provided text; however, key topics addressed by management included:
• China Royalties: Clarified that generic market share thresholds were met in 2025, necessitating a $2.1M cumulative royalty reduction and lower rates going forward.
• Inventory: Explained that Q3 revenue included ~$1.5M inventory drawdown at pharmacies/distributors.
• Debt: Confirmed debt-free status post-Q2 loan payoff.
• Expense Outlook: Confirmed R&D will rise 28-30% YoY to support clinical trials, while SG&A stays flat.
• Dose Escalation: Noted 80% of patients start at reduced doses; ongoing focus on education to support dose escalation and adherence.

Other Key Points:

• Fiscal year referenced in transcript is 2026 (likely a hypothetical or specific scenario context within the provided text).
• The company is archiving webcasts and slides for 90 days.
• Stock-based compensation (SBC) was $1.3M in SG&A and $0.7M in R&D for Q3 2026.
• Management emphasized the "dual indication" role of Nerlix in both early-stage (risk reduction) and metastatic (progression protection) settings.